You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

This message is from a valued third-party sponsor. It should not be considered a recommendation or endorsement by Benzinga.

Thermo Fisher Scientific Inc. (NYSE: TMO) Teams Up With Mainz BioMed (NASDAQ: MYNZ) To Stop Colorectal Cancer In Its Tracks

Mainz Biomed NV (NASDAQ: MYNZ) is on a mission to stop colorectal cancer in its tracks with its product ColoAlert®.

Clinical trials in the US and Europe have been successful, with ColoAlert’s sensitivities exceeding 90% for detecting colorectal cancer and over 80% for advanced adenomas. The company is gearing up to launch a clinical FDA trial in the U.S. next year. If that is successful, Mainz Biomed will be able to sell ColoAlert to millions of Americans at risk of colorectal cancer.

To further that goal Mainz Biomed just inked a deal with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”) to jointly develop and potentially commercialize ColoAlert in the U.S. Mainz Biomed said the collaboration will leverage combined technologies, instrumentation and information translation systems to enable Mainz Biomed to develop the proprietary assays for its mRNA-based next-generation CRC screening tests.

The support of existing and new partnerships isn’t the only backing the biopharmaceutical company is getting for ColoAlert. It recently announced Petra Smeltzer Starke, founder and CEO of a global growing hot yoga healthy lifestyle brand SweatNGlow, is now a brand ambassador. Meanwhile, Frankie Muniz, the actor turned racecar driver, is also backing the company as he speaks out about colorectal cancer cases in young people, which has surged 500% in the past twenty-two years.

To learn more about Mainz and ColoAlert click here. 

This is a paid ad. Please see 17b disclosure here for more information.